National Health (Listed drugs on F1 or F2) Amendment Determination 2017 (No. 3) (PB 32 of 2017) (Cth)
PB 32 of 2017
National Health (Listed drugs on F1 or F2) Amendment Determination 2017 (No. 3)
National Health Act 1953
I, KAREN BINNEKAMP, Assistant Secretary (Acting), Pharmaceutical Evaluation Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this determination under subsection 85AB(1) of the National Health Act 1953.
Dated 28 April 2017
KAREN BINNEKAMP
Assistant Secretary (Acting)
Pharmaceutical Evaluation Branch
Pharmaceutical Benefits Division
Department of Health
Part 1 Preliminary
Name of Determination
(1) This Determination is the National Health (Listed drugs on F1 or F2) Amendment Determination 2017 (No. 3).
(2) This Determination may also be cited as PB 32 of 2017.
Commencement
This Determination commences on 1 May 2017.
Amendment of National Health (Listed drugs on F1 or F2) Determination 2010
Schedule 1 amends the National Health (Listed drugs on F1 or F2) Determination 2010 (PB 93 of 2010).
Schedule 1 Amendments
(Section 3)
[1] Schedule 1, after item dealing with Balsalazide
Omit
Bacillus Calmette and Guerin, Connaught strain
[2] Schedule 1, after item dealing with Biperiden
Omit
Boceprevir
Insert
Blinatumomab
[3] Schedule 1, after item dealing with Chlorambucil
Insert
Chloramphenicol
[4] Schedule 1, after item dealing with Daclatasvir
Insert
Daclizumab
[5] Schedule 1, after item dealing with Gelatin-succinylated
Omit
Gestrinone
[6] Schedule 1, after item dealing with Nicotine
Insert
Nintedanib
[7] Schedule 1, after item dealing with Protein formula with amino acids, carbohydrates, vitamins and minerals without phenylalanine, and supplemented with docosahexaenoic acid
Insert
Protein formula with carbohydrate, fat, vitamins and minerals
[8] Schedule 1, after item dealing with Trametinib
Omit
Tranexamic acid
[9] Schedule 2, after item dealing with Trandolapril
Insert
Tranexamic acid
0
0
0